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Summary 
Synthetic peptide analogues of sequences in the HER-2 protooncogene (HER-2) were selected 
based on the presence of HLA-A2.1 anchor motifs to identify the epitopes on HER-2 recognized 
by ovarian tumor-reactive CTL.  19 synthetic peptides were evaluated for recognition by four 
HLA-A2 + ovarian-specific cytotoxic T  lymphocyte (CTL)  lines  obtained from leukocytes as- 
sociated with ovarian tumors. The nonapeptide E75 (HER-2, 369-377:KIFGSLAFL) was efficient 
in sensitizing T2 cells for lysis by all four CTL lines.  This peptide was specifically  recognized 
by cloned CD8 + CTL isolated from one of the ovarian-specific CTL lines.  E75-pulsed T2 cells 
inhibited lysis by the same CTL clone of both an HLA-A2 + HER-2h;e h ovarian  tumor and a 
HER-2h;g h cloned ovarian tumor line transfected with HLA-A2, suggesting that this or a struc- 
turally similar epitope may be specifically  recognized by these CTL on ovarian tumors. Several 
other HER-2 peptides were recognized preferentially by one or two CTL lines,  suggesting that 
both common and private HER-2 epitopes may be immunogenic in patients with ovarian tumors. 
Since HER-2 is a self-antigen,  these peptides may be useful for understanding  mechanisms of 
tumor recognition by T cells, immunological tolerance to tumor, and structural characterization 
of tumor  antigens. 
T 
he existence of CTLs in the leukocyte infiltrations  of 
ovarian tumors,  that when expanded in culture in the 
presence of IL-2 are capable of recognizing autologous, and 
HLA-matched allogeneic tumors provides strong support to 
the hypotheses that  these CTL recognize multiple private 
and/or common Ag on tumor and that these Ag can induce 
T  cell responses (1, 2).  A  critical step towards testing this 
modal is the identification of tumor-specific T cell epitopes. 
This goal is highly significant because it may lead to an un- 
derstanding of the immune responses to tumors, the reasons 
for failure of such responses to control tumor growth in vivo, 
and development of novel strategies for cancer therapy. Pro- 
cessing of tumor cellular proteins  may result in  CTL epi- 
topes. In general,  the ability of peptide ligand  to compete 
for receptor binding improves as its concentration increases, 
and the distinction between tumor and normal tissue reac- 
tivity may be predicated on the ability of peptides from an 
overexpressed protein to occupy a significant  number of MHC 
molecules in competition with other peptides according to 
the laws of mass action (3).  Based on these considerations, 
we proposed the HER-2/neu protooncogene (HER-2) 1 as a 
1  Abbreviations used in this paper: FBP, folate-binding protein;  HER-2, 
HER-2/neu  protooncogene; MCF, mean channel fluorescence number; 
TAL, tumor-associated lymphocytes; TAP, peptide transporter-associated 
proteins; (TAP1 and TAP2); TIL, tumor-infiltrating lymphocytes. 
potential target for a T cell response against epithelial tumors 
such as those in breast and ovary, because in a number of 
tumors the concentration  of this protein is increased by up 
to 100-200-fold over normal tissues.  Processing of this over- 
expressed protein may result in increased peptide supply, which 
may activate/reactivate an immune response against tumor 
(3). In support of this hypothesis, evidence from a large case 
analysis in breast cancer indicates that HER-2 overexpression 
corrdates with a favorable prognosis in patients with breast 
cancer having  a high  density of local lymphocyte infiltra- 
tion (4). 
The importance of HER-2 in the recognition of ovarian 
and breast tumors by CTL in vitro and in vivo has not yet 
been ducidated,  nor have the common epitopes of HER-2 
recognized by CD8 + CTL lines from different donors and 
cloned  CD3 +CD8 +CD4-  CTL  been  identified.  In  this 
study, we have identified common immunogenic epitopes of 
HER-2 recognized by four out of four and two out of four 
CD3 § CD4-CD8 + ovarian-specific  CTL lines that were iso- 
lated from tumor-associated lymphocytes (TAL) from HLA- 
A2 + ovarian cancer patients.  CTL clones isolated from one 
of these lines confirmed recognition of one common HER-2 
epitope,  and they suggest that  a peptide with  an identical 
or cross-reactive sequence is recognized by tumor-reactive CTL 
on ovarian tumors. Identification of common antigenic CTL 
epitopes of HER-2 may help to develop targeted immunother- 
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date the mechanisms  of tolerance towards  these epitopes. 
Materials  and Methods 
Synthetic Peptides and Monoclonal Antibodies.  HER-2 and con- 
trol peptides were synthesized by the Synthetic Antigen Labora- 
tory at  the M.D.  Anderson Cancer Center using  a solid-phase 
method and purified by HPLC. Identity of the final peptides was 
established by amino acid analysis. The purity of the peptides used 
in these experiments was  t>97%, mAb to CD3 (OKT3-FITC), 
CD4 (OKT4-FITC), and CD8 (OKT8-FITC) were obtained from 
Ortho Diagnostic (Raritan, NJ), mAb W6/32(anti-HLA,-A,-B, 
-C) from Dako (Dakopatts, Denmark),  and anti-HLA-A2 mAb 
BB7.2 (anti-c~-2  domain)  and MA2.1  (anti-cx-1  domain)  from 
American Tissue Culture Collection (ATCC, RockviUe, MD). mAb 
Ab2 against  HER-2 was obtained from Oncogene Science (Man- 
hasset,  NY). 
Target Cells and Cell Lines.  The human cell line 174CEM.T2 
(T2) was a kind gift from Dr. Peter Creswell (Yale University, New 
Haven, CT). These cells are defective in the normal antigen pro- 
cessing pathway and they express HLA-A2.1 occupied only by signal 
peptides (5). CIR transfectants C1R:A2 and CIR:A1 cells express 
HLA-A2.1  and HLA-A1,  respectively.  Parental Hmy2.C1R (class 
I reduced) cell line does not express any HLA-A, but expresses low 
HLA-B35. These cells were a generous gift from Dr. William E. 
Biddison (National Institute of Neurological Disorders, Bethesda, 
MD). Tumor lines and leukocytes of the donors of ovarian malig- 
nant ascites were phenotyped for HLA-A, -B, and -C antigens by 
the Blood Bank at the M.D. Anderson Cancer Center. Expression 
of HLA-A2 on freshly isolated  ovarian tumors and transfectants 
was confirmed by immunofluorescence using MA2.1 mAb. Ovarian 
tumor lines of known HLA phenotypes, MDAH 2774 (HLA-A3, 
24,B45,w57)  and  SKOV3(HLA-A3,28,B18(w6),35(w6),  Cw5), 
were also used as targets in these experiments. 
SKOV3 cells were transfected with the HLA-A2 expression vector 
RSV.5-neo containing the same full-length HLA-A2.1 cDNA ex- 
pressed in C1R:A2 cells (6) (kindly provided by Dr. W. Biddison), 
using the Lipofectin reagent and procedure as described by the 
manufacturer (Gibco Life Technologies, Grand Island, NY). After 
selection with G418, clones that expressed high levels of HLA-A2 
and HER-2 (as determined by immunofluorescence with MA2.1 
and Ab2 mAbsA) were selected for further experiments. 
HER-2 Peptide Binding to HLA-A2.1  To establish the ability of 
HER-2 peptides to stabilize HLA-A2 expression, the T2 MHC class 
I peptide stabilization assay was performed as described (7).  T2 
cells were incubated overnight with saturating amounts of all of 
the selected HER-2 peptides, as well as with positive and negative 
control peptides at the same concentration (50/xg/ml). Cells were 
then washed, stained with BB7.2 and W6/32 mAbs, and analyzed 
by flow cytometry as described (2, 7, 8). Fluorescence intensity 
and positions of the peaks were determined using an Epics  |  V profile 
analyzer with a log amplifier  (Coulter Electronics,  Hialeah, FL). 
Results are expressed  as the mean channel fluorescence  number 
(MCF) on a logarithmic scale corresponding to the peak of fluores- 
cence for HLA-A2 (8). 
Generation of Ovarian-specific CTL Lines and Clones.  CTL were 
generated by culturing freshly isolated tumor-associated lympho- 
cytes  (TAL) from ovarian  malignant  ascites in complete RPMI 
medium in the initial presence of autotogous ovarian tumor, 25-50 
U/ml of II.-2 (Cetus Corp., Emeryville, CA), and 250 U/ml of 
TNF-a (Genentech, South San Francisco, CA), for 2 wk, followed 
by  selection  of CD8+  cells  on  anti-CD8  mAb-coated  culture 
flasks (AIS Micro CELLector~; Applied Immune Sciences, Menlo 
Park, CA) and negative selection on anti-CD4 mAb coated flasks 
as described (9). Isolated CDS+CD4 -  cell lines designated CTLs 
1-4 were propagated in culture in complete RPMI medium sup- 
plemented with Ib2. CD3+CDS+CD4 -  clones were established 
by limiting dilution from CTb3 line as we described (1, 2). 
Identification of Antigenic  Peptides.  To identify the  antigenic 
HER-2 peptides, CTL lysis of T2 cells preincubated for 60 rain 
with each peptide was measured in a SlCr release cytotoxicity assay 
(1, 7). For titration of HER-2 peptides for recognition by CD8 + 
CTL, T2 cells were incubated with varied concentrations of  purified 
HER-2 peptides. For antibody inhibition experiments,  targets were 
preincubated with the appropriate antibody as described (2), then 
washed  and incubated with effectors. Percentage of specific lysis 
was determined from the equation (A  -  B)/(C  -  B)  x  100, 
where A is lysis ofT2 ceils by effectors in the presence of a peptide, 
B is spontaneous release from T2 cells in the presence of the same 
peptide but in the absence of effectors,  and  C  is the maximum 
51Cr release. The experiments were performed in triplicate, and the 
mean  _+ SD values were calculated from at least two separate ex- 
periments. Since even one amino acid change in peptide length at 
the COOH-terminal end can have dramatic effects on peptide rec- 
ognition (10), and identification of CTL epitopes is performed with 
synthetic peptides, cytotoxicity values were considered to indicate 
significant recognition of a peptide when the differences between 
mean  _+ SD values for percent of specific lysis of T2 cells prein- 
cubated with a peptide or medium were >110%, at an E/T ratio 
of 20:1 (10) and statistically  significant  (p <0.05). Cold target in- 
hibition  of cytolysis  was  performed using  51Cr-labeled ovarian 
tumors, OVA-1 (autologous with CTL-1), as well as SKOV3.A2.1E4 
transfectants  as "hot" targets and T2 cells pulsed with peptides 
as "cold" targets.  T2 cells were preincubated with HER-2 or con- 
trol peptides (50/~g/rnl) overnight, then washed and admixed with 
SlCr-labeled targets at 5:1 and 10:1 (cold/hot) target ratios. 
Statistical Analysis.  Values  obtained for percent of specific lysis 
by the same effectors of T2 cells preincubated with HER-2 pep- 
tides and percentage of specific lysis of T2 cells in the absence of 
exogenous peptides were examined by the Student's t test. Differ- 
ences were considered significant  when the p  <0.05. 
Results 
Identification of HER-2 Peptides That Stabilize HLa-A2.1 Ex- 
pression.  To identify the HER-2 epitopes recognized by these 
CTL,  19 peptides were selected from the HER-2 sequence 
based on the HLA-A2 anchor motifs based on the presence 
of Leu/Ile at position 2 (P2) and Val/Leu/Met at P9 (11, 12). 
The majority (16 out of 19) peptides selected for this study 
were nonamers.  Two octamers were included because they 
were part of overlapping epitopes. 15 out of 19 peptides con- 
tained Leu (P2), while two peptides contained Ile (P2) and 
two peptides  contained Val  (P2),  Only octa and  decamers 
were found in the HER-2  sequence to contain Met at P2, 
and consequently these peptides  were not  included in the 
present study. Peptides were selected from signal,  extracel- 
lular,  transmembrane,  and cytoplasmic domains of HER-2 
(13). Priority was given to peptides from the regions 364- 
474  and  781-859 because they contain  the highest  density 
of continuous  and  overlapping  epitopes  with  HLA-A2.1 
2110  HER-2-reactive Cytotoxic T Lymphocytes binding motifs. Peptides were also selected from the signal 
and transmembrane domains of HER-2 because hydrophobic, 
Leu-, Ile-, and Val-rich peptides were found bound on HLA- 
A2 of both T2 and C1R:A2 cells (5, 14), were described as 
CTL  epitopes  (10),  and  may be  bound  to  HLA-A2  in 
transporter-associated  proteins (TAP)-deficient targets (5). The 
peptides selected for this study represent more than 50% of 
all nonamers that are potential HER-2 epitopes with HLA- 
A2 anchor motifs (11, 12). 
Since both P2 and P9 anchors and residues from the cen- 
tral area of peptide contact HLA-A2 and define the affnity 
of a peptide to the presenting molecule (12),  to determine 
the binding ability of HER-2 peptide analogues, expression 
of HLA-A2 on T2 cells was determined in the presence of 
each HER-2 peptide and the corresponding control peptides. 
All peptides were tested for binding to the MHC class I in 
the HLA-A2 stabilization assay using T2 as indicator cells 
(7, 8). To establish that the results reflect MHC class I heavy 
chain expression indicative of absolute binding and not only 
the effects of peptide-induced conformational changes (8) that 
may affect the reactivity of mAb with the peptide-binding 
pocket, T2 cells were stained with both W6/32 (anti-class 
I monomorphic) and BB7.2 (anti-HLA-A2 c~-2 domain) mAb. 
As shown in Table 1, 9 out of 19 HER-2 peptides (ranked 
1-9 based on their HLA-A2- stabilizing ability) induced a 
greater than twofold increase in MCF for HLA-A2 expres- 
sion,  compared to negative control peptide C61,  as deter- 
mined with BB7.2 mAb. Similar results were obtained after 
staining with MA2.1 mAb (data not shown). HLA-A2 stabili- 
zation for E75, E90, and E89 was peptide concentration de- 
pendent in the range 1-50 #g/ml (not shown). This sug- 
gests that these peptides have higher stabilizing ability of both 
conformational epitope BB7.2, as well as HLA-A2 molecule 
expression than the other 10 peptides (ranked 10-19), which 
were designated as peptides with low stabilizing ability for 
HLA-A2.1.  Five other peptides, E70,  E71,  E72,  D97,  and 
D99, did not affect serological epitope W6/32  expression, 
suggesting that they bound poorly to HLA-A2. Of these pep- 
tides, the octamer D97 induced a significant increase in BB.7.2 
epitope expression, suggesting induction of a conformational 
epitope rather than stabilization of HLA-A2 expression. In 
contrast, BB.7.2 bound poorly to T2 cells pulsed with pep- 
tide E74 compared with W6/32. The implication of this sero- 
logical analysis is that HER-2 peptides, in addition to having 
binding and stabilizing effects on HLA-A2 expression, may 
lead to conformational changes in the Ag-binding pocket. 
Recognition of HER-2 Peptides by Ovarian Tumor-reactive 
CTL.  To identify HER-2 peptides recognized by ovarian 
tumor-reactive CTL lines, four CD8 § CTL lines designated 
CTLs  1-4  were generated from cultured TAL from four 
different HLA-A2 +  donors  after  CD8 +  cell  selection on 
anti-CD8 antibody-coated plates. These CTL lines were 100% 
CD3 +, 100% CD8 + , and 0-2% CD4 + . This approach was 
considered necessary because the Ag specificity of CD3 + 
CD8 +  CD4-  CTL isolated from tumor-infiltrating lympho- 
cytes (TIL)/TAL, which have been in culture for 2 wk, will 
not be diluted or masked by the overgrowth of CD4 + cells, 
which is encountered in long-term TIL/TAL cultures. To 
avoid changes in the Ag spedfidty, the isolated CD3+CD8 + 
CD4-  lines were not restimulated with autologous or allo- 
geneic HLA-A2 + tumors. These CTL lines recognized auto- 
logous and aUogeneic  HLA-A2 + ovarian tumors, but  not 
HLA-A2- ovarian tumors or lines,  as illustrated in Table 2. 
Since freshly isolated ovarian tumors from different donors 
may be antigenicaUy heterogeneous or may express variable 
levels of HER-2, we needed as target a cloned ovarian tumor 
of high and stable HER-2 protein expression and known HLA- 
phenotype having HLA-A2 in common with the effectors. 
Tumor cells of the SKOV3 line, which overexpresses HER-2 
protein (15), were transfected with the HLA-A2 gene. TAP1 
and TAP2 message expression in SKOV3 is increased in par- 
allel with HLA class I by IFN-"/treatment (16), suggesting 
unimpaired Ag-presenting ability.  A clone SKOV3.A2.1E4 
expressing  high  and  stable  levels  of HER-2  protein  and 
HLA-A2 was used as a target in these experiments. Four HLA- 
A2 + ovarian CD8+CD4 -  CTL lines lysed SKOV3.A2.1E4 
clone in addition to autologous and  allogeneic HER-2hig  h 
HLA-A2 +  tumors.  They  did  not  recognize  HLA-A2 +, 
HER-2 l~  ovarian cell lines.  Furthermore, they did not lyse 
K562 cells, indicating that they did not express NK or LAK 
activity (Table 2). Autologous tumor lysis was inhibited by 
mAb to CD3 TCR (OKT3) and HLA-A2 (MA.2.1), but not 
by anti-HLA-DR mAb, suggesting that they can recognize 
Ag presented by HLA-A2 (data not shown). 
To evaluate  whether these CD8 +  CTL  recognized the 
same or different HER-2 peptides, lysis of T2 cells preincubated 
with each peptide was tested with all CTL lines.  Both high 
and low affinity peptides were tested in the same experiment 
since it has been reported that a melanoma CTL epitope is 
derived from low affnity HLA-A2-binding peptides (17). For 
increased stringency in epitope identification, recognition of 
an HER-2 peptide was considered significant based on con- 
vergence of results of statistical analysis of differences in cy- 
totoxicity data (18,  19)-and assigning a cut-off value of at 
least 10% for the differences between recognition of T2 cells 
exogenously loaded with HER-2 peptides and T2 cells pre- 
senting only endogenous peptides. This approach was neces- 
sary because we wanted to identify peptides that, based on 
the levels of observed lysis, are either recognized with higher 
affinity than others or their recognition reflects the presence 
of a higher percentage of specific reactive clones. 
Based on comparison of cytotoxicity values for T2 cells, 
lysis  by  CD8 +  CTL1-4  in  the  presence  and  absence  of 
HER-2 peptides, CTL-1 and CTL-2 recognized mainly pep- 
tide E75 (Fig. 1). CTb3 recognized, in addition to E75, three 
other peptides (E90, E89, and C85), but it did not recognize 
the remaining 15 peptides. CTL-4 recognized four of the pep- 
tides tested, including E75 and C85.  CTI.-4 recognized, at 
a lesser extent than E75 and C85, two other HER-2 peptides 
residues, 799-807 (E71) and 835-842 (E73). Peptides E71 and 
E73 were not recognized by the other three CTL lines, even 
when reconstitution of the epitopes was attempted at either 
higher peptide concentrations or higher E/T ratios, and may 
represent private epitopes for CTb4  (Fig.  1). Since CTb4 
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BB7.2  W6/32 
Code  Position  1  2  3  4  5  6  7  8  9  10  MCF*  Rank*  MCF  Rank 
HER.-2  peptides 
E91  5-13 
D97  42-49 
Dl13  48-56 
E75  369-377 
E77  391-399 
E76  402-410 
E78  457-465 
E93  466-474 
E92  650-658 
E88  689-697 
E70  793-801 
E90  789-797 
E71  799-807 
E72  828-836 
E73  835-842 
E74  838-846 
E89  851-859 
C85  971-979 
D99  1089-1098 
Control peptidesS 
HER-2 
C81  971-979 
C61  968-977 
Folate-binding proteinfl 
E38  112-120 
E37  25-33 
E41  245-253 
No peptide 
A  C 
H  D 
H  Y 
K  F 
P  Q 
T  E 
S  R 
A  L  I 
P  L  T 
R  L  L 
T  V  Q 
C  L  T 
Q  L  M 
Q  I  A 
Y  L  E 
D  V  R 
V  L  V 
E  L  V 
D  L  G 
R  W  G  L  L  L  82  9  306  8 
M  L  R  H  L  52  12  167  18 
Q  G  c  Q  v  v  155  2  496  2 
G  S  L  A  F  L  131  3  474  4 
P  E  Q  L  Q  V  61  10  216  11 
E  I  T  G  Y  L  109  6  358  5 
E  L  G  S  G  L  60  11  208  12 
H  H  N  T  H  L  113  5  293  9 
S  I  I  S  A  V  128  4  324  6 
Q  E  T  E  L  V  109  7  481  3 
L  V  T  Q  L  M  35  18  172  17 
S  T  V  Q  L  V  164  1  515  1 
P  Y  G  C  L  L  42  16  173  15 
K  G  M  S  Y  L  32  19  166  19 
D  V  R  L  V  51  13  234  10 
L  V  H  R  D  L  36  17  203  13 
K  S  P  N  H  V  82  8  310  7 
S  E  F  S  R  M  47  14  194  14 
M  G  A  A  K  G  L  44  15  172  16 
E  L  V  S  E  V  S  K  V  76  261 
R  F  R  E  L  V  S  E  F  S  37  182 
N  L  G  P  W  I  Q  Q  v  77  N.D. 
R  I  A  W  A  R  T  E  L  34  N.D. 
L  L  S  L  A  L  M  L  L  38  N.D. 
34  172 
" Mean channel fluorescence (MCF) corresponding to the peak of fluorescence for T2 cells preincubated with 50/~g/ml  of each peptide was deter- 
mined for all peptides in the same experiment as described in the Materials and Methods. MCF for both W6/32 and BB7.2 are presented and compared 
to confirm the increase in MHC class I heavy chain expression. 
* Peptides are ranked in decreasing order of their ability to increase HLA-A2.1 expression. 
The variant peptide of C85 containing three substituted residues F ~  V(P6), R "" K(PS), and M --~ V(P9) was used as positive control because 
the resulting variant (C81) contains four dominant and strong anchor residues (11, 12) reported to favorize binding to HLA-A2. The peptide C61 
(HER-2: 968-977) contains HLA-B8 anchors and was used as negative control. 
II Folate-binding protein (FBP) peptides were selected from the FBP sequence based on the concordance  of T cell epitopes predicted by the computer 
program, ANT.Find.M  (3), and the presence of HLA-A2-specific anchor motifs (11). 
was  isolated  from  the  ascites  corresponding  to  previously 
reported TAL-24, these results confirm the recognition of a 
peptide  from the area  968-984  (C85)  as  a potential  T  cell 
epitope derived from HER-2 or a  structurally  similar pep- 
tide HLA-A2 complex (20). Peptide E75 was recognized by 
all four CTL lines, C85 by two out of four CTL lines, while 
peptides  E89 and E90 were recognized by CTL-3, and E71 
and E73 by CTL-4. All four CTL lines failed to specifically 
recognize a number of HER-2 peptides presented by T2 cells 
with canonical HLA-A2 anchors at P2 and P9 and different 
central  sequences,  including Dl13,  which was  reported  to 
bind HLAoA2 with high affinity (12). All CTL lines showed 
low levels  of lysis  of T2 cells  without  exogenous peptides 
(T2 cells present a number of signal peptides) (5), comparable 
2112  HER-2-reactive  Cytotoxic T Lymphocytes Table  2.  Recognition of HLA-A2 + Tumors  by 
Ovarian.specific CTL Lines 
Percent of specific lysis* 
Targets*  CTL-1  CTL-2  CTL-3  CTL-4 
Auto-T  (HER-2+,A2 +)  47  65  28  41 
Allo-T (HER.-2+,A2 +)  40  41  14  38 
SKOV3.A2.1E4 
(HER-2 §  +)  45  39  42  84 
Allo-T (HER.-2- ,A2-)  5  15  NT  3 
2774 (HEK-2-,A2-)  0  0  0  4 
K562 (HER-2-,A2-)  1  3  3  4 
* Percent  specific lysis is shown for an effector to target ratio of 20:1. 
Target lysis was determined in a 5-h 51Cr release assay. NT, not tested. 
Auto-T and AIIo-T represent autologous and allogeneic freshly isolated 
ovarian tumors.  SKOV3.A2.1E4  is an ovarian tumor clone expressing 
HLA-A2.  2774  is a  human ovarian tumor line. 
to lysis of the NK targets, K562 cells. These results show 
that  ovarian tumor-reactive CTL  can recognize common 
HER-2 epitopes, although the pattern of peptide recogni- 
tion is different for each line. 
Recognition of E75 by CTL.3  Clones.  Results presented 
above are suggestive of common HER-2 peptide recognition 
by four distinct CTL lines. We wanted to establish whether 
E75 is specifically recognized by cloned CTL, and whether 
it may correspond to an epitope recognized by the same CTL 
clone on ovarian tumors that overexpress HER-2. CTbl and, 
to a lesser extent, CTL-2, appear to be highly restricted in 
their recognition of E75. This can cause the results of pep- 
tide specificity experiments with cloned CTL-1 and -2 to ap- 
pear biased in the favor of E75.  To address the question of 
whether reactivity to E75 was a property of distinct non-cross- 
reactive clones from a line of multiple HER-2 spedficities, 
and to establish whether these clones recognize E75 in a pep- 
tide concentration-depependent and -specific manner, clones 
were developed from CTb3 by stringent limiting dilution 
and further expanded in culture. 
CTL-3 line did not lyse the CIR or CIR:A2 cells (Fig. 
2 A). Since C1R:A2 and SKOV3.A2.1E4 were transfected 
with the same plasmid carrying the same HLA-A2 gene, this 
suggests that the endogenous peptides recognized on SKOV- 
3.A2.1E4 by CTL-3 may be different from the ones presented 
by C1R:A2 cells. Both E75 and C85 were recognized by CTL-3 
and CTb4 when presented by C1R:A2 but not by CIR:A1 
transfectants (data not shown). Concentration-dependent rec- 
ognition of E75,  C85,  and E90 was observed with CTL-3 
(Fig. 2 B). This recognition was confirmed in independently 
performed experiments. Documentation of restricted expres- 
sion of FBP on ovarian tumors suggests the possibility of 
cellular immune recognition ofFBP peptides (21). CTL-3 did 
not recognize two peptide analogues of FBP, residues 112- 
120 (E38) and residues 245-253  (E41) (Fig.  2 A). FBP pep- 
tides were selected to include HLA-A2-binding anchors and 
to exhibit high (E38) and low (E41) HLA-A2- binding affinity, 
respectively (Table 1). Similarly, CTL-3 did not recognize two 
peptide analogues of the Muc-1 core peptide (22), D125 and 
D132. Recognition by cultured ovarian TAL of Muc-1 core 
exposed on ovarian tumors and of Muc-1 gene transfected 
and expressed by EBV-B cell lines has been suggested (23). 
Muc-1 core sequence lacks canonical HLA-A2 anchors at cor- 
rect distances to allow binding to the main HLA-A2 pockets 
(21), but its recognition has been described mainly as non- 
MHC  restricted (24).  Therefore, in both Muc-1 peptides, 
GLTSAPDTRV (D125) and SLADPAHGV (D132), HLA-A2 
anchors were introduced (underlined) to engage binding and 
to present the intervening sequence to TCRs. These results, 
together with the results presented in Fig.  1,  suggest that 
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CTL-3 line contains clones that are specific for particular pep- 
tide epitopes. 
Two clones, 3C4F and 3B4E, isolated from CTL-3 line that 
recognized E75 but not E90 or E89 peptides presented by 
T2 cells, are shown in Fig. 2 (C and D). Recognition of T2 
cells incubated with the same concentration of E75 suggest 
that clones 3C4F and 3B4E are specific for peptide E75 (Fig. 
2, C and D).  Recognition of E75 by these two clones was 
compared over a range of concentrations (10 nM-10/~M) (Fig. 
3 A). At an E/T ratio as low as 4:1, peptide E75 reconstituted 
T cell recognition by clone 3C4F at a concentration (100 riM) 
similar to that reported for an HLA-A2-restricted epitope 
gpl00 and an HLA-Al-restricted epitope from MAGE-3 rec- 
ognized by melanoma-specific CTL (25,  26), but at higher 
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Figure 3.  Inhibition of ovarian tumor recognition  by clone CTIc3C4F by T cell epitope  E75. (A) Dose-response  recognition  of peptide  E75 by 
clones 3C4F (m) and 3B4E (O). Serial dilutions  of peptide  E75 were incubated  with 3,000 T2 cells for 60 min. CTL were added at a E/T ratio 
of 4:1, and a standard  5-h cytotoxicity  assay was performed.  Lysis of T2 cells preincubated  with E90 at  10/~M was <5% by both CTL clones. (B 
and C) Cold-target inhibition of lysis of freshly isolated ovarian tumor OVA-1 (B), and ovarian tumor clone SKOV3.A2.1E4 (C) by T2 cells preincubated 
with peptides E75 ('),  E90 ([2]), and D132 (A). The effector (CTb3C4F clone)/hot target  ratio  was  10:1. Peptide pulsed T2 cells (cold targets) 
were added in the assay at 5:1 and  10:1 cold/hot target  ratios.  Inhibition of lysis was determined  in a 5-h stCr release assay. Results  are presented 
as percentages of inhibition  of tumor target lysis by clone 3C4F, which was 46% for OVA-1 (B) and 28% for SKOV3.A2.1E4 (C). Lysis of parental 
control  targets SKOV3 (HLA-A2-) was 6% and of D132-pulsed T2 cells was 5% at the same E/T ratio. (D) Lysis of SKOV3.A2.1E4 was inhibited 
by anti-HLA class I (W6/32 mAb) but not by anti-HLA-DR (L243 mAb) at both  10:1 ([])  and 5:1  (l)  E/T ratios. 
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gpl00 and HER-2, significantly higher by at least two orders 
of magnitude than those of HLA-A2.1-restricted viral pro- 
teins (27). 
To confirm that clone 3C4F recognizes a natural epitope 
associated  with HLA-A2 on ovarian tumors, we examined 
the ability of E75  and E90 pulsed T2 cells to inhibit lysis 
of freshly isolated OVA-1 because CTI~I, autologous with 
this tumor, recognize only E75. Significant inhibition of lysis 
was observed by T2 cells pulsed with E75 but not with E90 
(Fig. 3 B). Since antigen expression on freshly isolated ovarian 
tumors can be heterogeneous, to confirm that E75 represents 
an epitope presented by HLA-A2 on an ovarian tumor clone, 
the ability of E75 pulsed T2 cells to inhibit lysis of clone 
SKOV3.A2.1E4 was examined. Both OVA-1 and SKOV3.A2 
transfectants share only HLA-A2 with effectors and express 
HER-2 on the surface,  OVA-l:  79%  HER-2 + cells,  MCF 
=  29; SKOV3 (positive control): 100% HER-2 + cells MCF 
=  40;  SKOV3.A2.1E4:  100% HER-2 + cells, MCF  =  40; 
C1R:A2 cells (negative control) MCF  =  0.7. Ovarian clone 
SKOV3.A2.1E4  lysis  by  3C4F  clone  was  inhibited  by 
anti-MHC class I (W6/32) but not by anti-MHC class II 
mAb (Fig. 3 D). Again, significant inhibition of lysis by clone 
3C4F was observed in the presence of E75. Control peptide 
D132, which was not recognized when pulsed on T2 cells, 
failed to redirect clone 3C4F lysis (Fig. 3 C). Therefore, E75, 
which is recognized by four CTL lines and cloned CTL iso- 
lated from one of these lines,  and which specifically inhibits 
recognition of ovarian tumors, may be a natural common 
HER-2 epitope recognized by ovarian-specific  CTL. 
Discussion 
In this study, we have investigated recognition of synthetic 
peptide  analogues  of  HER-2  epitopes  containing  HLA- 
A2-binding motifs by CD8+CD4 -  CTL lines  and clones 
isolated from TAL with ovarian tumors. We have identified 
one common epitope (E75)  that is dominantly recognized 
by four out of four CTL lines. Of 19 peptides tested, another 
common epitope, C85, is recognized by two out of four lines. 
Several other epitopes, E89, E90,  E71,  and E73,  are recog- 
nized only by one of the four CTL lines used,  suggesting 
that they may be either private epitopes for these CTL or 
clones recognizing these epitopes are present with low fre- 
quency in the other CTL lines. The second possibility is more 
likely because the pattern of concentration-dependent recog- 
nition for E90 is similar with that of E75 and C85. In certain 
experiments, statistical analysis found that recognition of E89 
and  E90  by  CTL-2  and  CTL-4,  and  E91  by  CTI~2  was 
significantly different from control targets, but the levels of 
recognition were lower (5-7%) than the cut-off value.  We 
have observed that some ovarian CTL cultures lose the ability 
to recognize a number of these peptides over time probably 
because of gradual loss of lytic function or overgrowth of 
CTL of different specificities (Ioannides, C. G., and B. Fisk, 
unpublished data). We confirmed the specificity of E75 rec- 
ognition by using two clones isolated from one of the CTL 
lines.  E75 effectively inhibited lysis by CTL clones of both 
a freshly isolated ovarian tumor and an ovarian tumor line 
transfected with HLA-A2, indicating that the epitope recog- 
nized is not a culture artifact. Control peptides containing 
HLA-A2 anchor motifs (11, 12) but different intervening se- 
quences failed to inhibit lysis, suggesting that a natural pep- 
tide with an identical or cross-reactive sequence is immuno- 
genic in HLA-A2 ovarian cancer patients and may be presented 
on ovarian tumors. 
Both E75 and C85 were recognized with different efficien- 
cies by CTL1-4 at the same peptide concentration. This may 
be caused by the existence of clones in these CTL lines that 
recognize other as yet unknown antigens. The existence of 
multiple distinct ovarian Ag expressed simultaneously on the 
same tumor clone has been shown by analyzing recognition 
of ovarian clones by CTL isolated from TAL (1). Ovarian- 
specific CTL lines restricted by HLAoA2 recognize common 
epitopes present on allogeneic HLA-A2 + ovarian tumors or 
lines, but not on HLA-A2 § melanomas. Individual ovarian- 
specific CTL lines were found to recognize multiple Ag epi- 
topes. Some of the common determinants may be expressed 
on other HLA-A2 + epithelial tumors (2,  3).  We have pre- 
viously shown that ovarian TAL can recognize Muc-1 core 
peptides and HER-2, 968-984, a longer analogue of C85 pep- 
tide (HER-2, 971-979)  (20).  CTL4 was isolated from TAL- 
24 used in these studies (20,  23).  Recognition of Muc-1 by 
at least some of the clones derived from the CTL lines used 
in this study is likely. Although the percentage of tumor cells 
expressing Muc-1 in a tumor sample is variable and its ex- 
pression is heterogenous, most ovarian tumors (>80% of se- 
rous adenocarcinomas) have been reported to express Muc-1 
(23).  Another HER-2 peptide, 654-662,  derived from the 
transmembrane domain, was found to be recognized by TIL 
isolated from non-small cell lung cancer and developed by 
different methods (19). HER-2  is  expressed in  ,,o30%  of 
ovarian and breast carcinomas. However, its expression is rel- 
atively stable over time through the clinical course of inva- 
sive breast cancer, it is relatively congruent at all metastatic 
sites, and it is not affected by tumor heterogeneity (28). This 
has potential clinical applications because it may allow devel- 
opment of therapies based on HER-2  targeting (28). 
Previous studies have shown a direct relationship between 
HER-2  overexpression and  sensitivity to  CTL  of ovarian 
tumors (18). Since overexpression of HER-2 may induce ex- 
pression of other proteins that can provide peptides (18) with 
the same or cross-reactive sequences, gene and protein sequence 
databases  were searched for homologous sequences.  100% 
matches for both C85 and E75 were not found. For E75 only 
EGF-R (HER-l), HER-3, and HER-4 gave matches for the 
main HLA-A2 anchors at P2, P6, and P9, but nonconserva- 
tive changes (underlined) were found in positions  1,  3,  5, 
and 7 (EGF-R, residues 364-372:SISGDLHIL, HER-3, resi- 
dues 356-364:KILGNLDFL, HEK-4:KINGNLIFL). Central 
positions are expected to be contact points for TCR (15, 29). 
Matches for peptide C85 appear in EGF-K, ERB.B3, DNA- 
directed P,  NA  polymerase (KPB-1),  and in  an  unknown 
nuclear protein (UL2-1). Nonconservative changes in the se- 
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tacts such as P4 and P7 in RPB-1 and P5 in UL2-1. Based 
on recent crystallography data, the peptide termini are bound 
to HLA-A2 similarly but the central area of the peptide adopts 
different conformations that represent the epitopes recognized 
by TCK (29). Therefore, the nonconservative changes in the 
sequence of the homologous peptides from the other members 
of the HER family may affect epitope conformation and if 
these peptides are processed, presented,  and recognized by 
TCR may constitute the equivalents of variants of peptides 
derived from the HER-2 protein. 
As for the other tumor Ags (10,  25,  26),  validation  of 
HER-2 epitopes requires identification  and quantitation  of 
peptides bound to HLA class I on ovarian tumors. Since E75 
lacks charged residues in the central area,  it will be impor- 
tant  to determine whether the same or conservatively sub- 
stituted peptides from other proteins are naturally processed 
and presented to CTL.  With  the exception of E75 recog- 
nized by all four CD8 + CTL,  and in part of C85,  which 
confirms our previous findings with unseparated CTL-TAL 
(20), three CTL recognized distinct HER-2 peptides at low 
level. These peptides were different in each system and their 
HLA-A2-stabilizing ability was variable over a wide range 
of concentrations. E89 binding affinity to HLA-A2 is at least 
three to four orders of magnitude  lower than  of naturally 
processed viral peptides (12),  suggesting that the affinity of 
TCR for E89-HLA-A2 complexes may be high.  This may 
also be true for C85. The affinity of a peptide for HLA-A2 
is not the determining factor for the abundance of particular 
peptide presented by HLA-A2 (30). Other important factors 
are protein concentration and the processing efficiency of an 
antigenic  peptide  (30). 
The  mechanisms  of HERo2 overexpression  reflect  gene 
amplification and upregulation of transcription (31). The in- 
volvement of translational, posttranslational mechanisms, or 
reduced rate of HER-2 turnover in HER-2 overexpression 
in cancer cells are still unclear (31). At this time, there is no 
simple explanation for the distinct pattern of peptide recog- 
nition between these lines. All tumors autologous with these 
CTL overexpressed  HER-2 protein at similar levels that were 
consistent with HER-2 receptor overexpression when ana- 
lyzed using monoclonal antibody Ab2 that is specific for the 
extracellular  domain of HER-2 (e.g.,  the levels  of HER-2 
expression were similar for OVA-1 and OVA-4 tumors [an- 
tologous with  CTL-1  and CTL-4]:  OVA-l,  79%  HER-2 + 
cells,  MFC  =  29,  OVA-4,  100%  HER-2 + cells,  MFC  = 
34, control OVA-17, 21% HER-2 + cells, MFC  =  4). How- 
ever, CTL-4 associated with OVA-4 recognized in addition 
to E75 three other peptides. It is possible that these peptides 
if presented are processed by the tumor with different effiden- 
cies (30).  It is also possible that while for self-proteins the 
tolerance is not absolute, as shown for melanoma TIL specific 
for either MART-1 or gpl00 (10,  25), elimination  of high 
affinity T  cells for a number of epitopes by tolerance may 
affect CTL with distinct  specifidties in each individual  (10, 25). 
Processing of overexpressed HER-2 in cancer cells may lead 
to peptides that differ in quantity from the HER-2 epitopes 
found on normal cells. Since HER-2 is present in normal ep- 
ithelial tissues at lower levels and the protein concentration 
may be a limiting factor in epitope presentation,  it will be 
important  to determine how widely CTL-mediated HEK-2 
recognition is observed in ovarian and breast cancer patients, 
and whether such CTL can cause tumor rejection and show 
toxicity towards normal  tissues. 
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